Wang B.J.,The Eighty first Hospital of Peoples Liberation Army |
Zhang B.,The Eighty first Hospital of Peoples Liberation Army |
Yan S.S.,The Eighty first Hospital of Peoples Liberation Army |
Li Z.C.,The Eighty first Hospital of Peoples Liberation Army |
And 7 more authors.
Diseases of the Esophagus | Year: 2016
Currently published studies on the relationship between hormonal and reproductive factors and esophageal cancer (EC) risk in women have yielded contradictory findings. For a better understanding of this relationship, we first performed this meta-analysis by pooling all available publications. Sixteen independent studies were retrieved after a comprehensive search in PubMed and Embase databases. The pooled relative risks (RRs) with 95% confidence intervals (95% CIs) were calculated. The pooled RRs implicated that hormone replacement therapy was negatively associated with the risk of EC (RR = 0.72, 95% CI 0.60–0.86, P < 0.001) and esophageal squamous cell carcinoma (RR = 0.68, 95% CI 0.48–0.97, P = 0.031). Menopausal women were at an increased risk of EC (RR = 1.47, 95% CI 1.07–2.03, P = 0.018), particularly esophageal squamous cell carcinoma (RR = 1.66, 95% CI 1.12–2.48, P = 0.012). Additionally, decreased risk of EC (RR = 0.79, 95% CI 0.68–0.92, P = 0.003) and esophageal adenocarcinoma (RR = 0.66, 95% CI 0.53–0.82, P < 0.001) was demonstrated among women with breast-feeding history. Moreover, such associations were more significant among Caucasians, but not Asians. Our study suggests that menopause is an independent risk factor for EC, while hormone replacement therapy and breast-feeding history play a protective role against EC, particularly among Caucasians. All results are consistent with the hypothesis that effects of estrogen may lower the risk of EC in women. © 2015 International Society for Diseases of the Esophagus Source
Yan S.,The Eighty first Hospital of Peoples Liberation Army |
Yan S.,Nanjing Medical University |
Xu D.,Nanjing Medical University |
Jiang T.,The Eighty first Hospital of Peoples Liberation Army |
And 13 more authors.
Tumor Biology | Year: 2014
Cluster of differentiation 24 (CD24) has been implicated in the development of cancer. Several single nucleotide polymorphisms (SNPs) in CD24 gene are reported to exert diverse effect on cancer risk. However, the association between CD24 SNPs and cancer risk remains unclear due to contradictory published findings. We performed a meta-analysis by pooling all available published studies on the susceptibility of CD24 rs52812045 and rs3838646 polymorphisms to cancer. The pooled odds ratios (ORs) with 95 % confidence intervals (95 % CIs) were calculated. There were five independent case–control studies with 5,539 cases and 10,241 controls included into the present study. The pooled results showed that no appreciable relationship was identified between any of the SNPs of CD24 and cancer risk. Interestingly, a protective role of the CD24 rs3838646 polymorphism was found in the risk of breast cancer, but lack of statistical significance (del allele vs. TG allele: OR = 0.89; 95 % CI, 0.79–1.01; POR = 0.063; del/del vs. TG/TG: OR = 0.70; 95 % CI, 0.44–1.12; POR = 0.135; del/TG vs. TG/TG: OR = 0.91; 95 % CI, 0.80–1.04, POR = 0.180; del/del + del/TG vs. TG/TG: OR = 0.90; 95 % CI, 0.79–1.03; POR = 0.123; del/del vs. TG/TG + del/TG: OR = 0.69; 95 % CI, 0.44–1.08, POR = 0.105). Our study firstly provides the evidence that SNPs (rs52812045 and rs3838646) of CD24 may not modify the risk of cancer. Nonetheless, more individual studies with high quality are needed for further elucidation. © 2014, International Society of Oncology and BioMarkers (ISOBM). Source